Preliminary Programme 13th IMW 2011
Transcript of Preliminary Programme 13th IMW 2011
-
8/8/2019 Preliminary Programme 13th IMW 2011
1/12
13THIMW
PARIS2011
May 3-6, 2011
Paris, Carrousel du Louvre
Abstracts Submission: from June 2010 to January 2011
Registration: Opening June 2010
PRELIMINARYPROGRAM
ME
13h InnIn
MYM WKShP
-
8/8/2019 Preliminary Programme 13th IMW 2011
2/12
Welcome to Paris
Dear Colleagues and Friends,It is both a privilege and an honour to invite you to attend the XIIIth International Myeloma Workshop to be held inParis from May 3 to 6, 2011.In continuation with the previous organizers of this important biannual event, we aim to provide a compelling
scientic programme highlighting emerging advances in our understanding of the biology and treatment of mye-loma disease. We also aim to stimulate lively debate discussion within the myeloma community and to contributeto efcient diffusion of medical information.Striving to further improve the quality of the meeting through various initiatives is another exciting task for us. Thelocation of the Workshop, in the Carrousel du Louvre which is right in the city centre, will ensure that you all enjoyboth the meeting and the fascinating city of Paris.
We are very much looking forward to welcoming you to Paris in May 2011!
Jean-Paul Fermand Thierry Facon Philippe Moreau
C F BSCS
Submit a abstract based o your scietic work i oe of te followig categories:
- Section A: Basic Biology- Section B: Boe Disease (icludig Imagig)- Section C: Cliical Studies (icludig rasplatatio)- Section D: Precliical Studies ad new Drugs- Section E: pidemiology, Progostic Factors, Quality of ife, Disease Complicatios ad reatmet oxicities- Section F: ter Plasma Cell Dyscrasias
Abstracts will have to be submitted directly on the Internet.They will be mainly considered for poster presentation, only a few abstracts will be chosen for oral presentation.Accepted abstracts will be published in the Haematologica Journal (supplement).
geda
Submission opening: Jue 2010Submission deadline: Jauary 10, 2011Notication of acceptance: Marc 2011
For further information on abstracts submission, please visit the website:
www.myeloma-paris2011.com
SUBMI n BSC BF JnUY 10, 2011!
-
8/8/2019 Preliminary Programme 13th IMW 2011
3/12
PIMInY PGMM
uesday May 3 Wedesday May 4 ursday May 5 Friday May 6
8:00
0:00
0:30
2:30
4:00
6:00
6:30
7:30
8:30
9:00
9:15
20:30
21:30
23:00
newly diagosed MM < 65 yrs:facts & questios
Chair:D. Reece & V. Hungria
How I treat?V. Rajkumar
What are the current asked questions?Cooperative groups
CelgeeSymposium
The Continuum of Care for theMultiple Myeloma Patient
Chair:K. Anderson &J.-L. Harousseau
Molecular patways /
geetics
Chair:H. Avet-Loiseau & M. Chesi
PnInG KCoffee break
Visit of exhibition & posters area
ucVisit of exhibition & posters area
Coffee breakVisit of exhibition & posters area
Coffee breakVisit of exhibition & posters area
Coffee breakVisit of exhibition & posters area
Coffee breakVisit of exhibition & posters area
Coffee breakVisit of exhibition & posters area
Boe disease: frompysiopatology to treatmet
Chair:R. Bataille & B. Durie
Waldestroms awardIntroduced byR. Kyle
Welcome receptio at teMuse du ouvre
Debate I:Post ig dose terapy, otig,
cosolidatio or maiteace?
Chair: J. Blad ;M. Attal & J.-P. Fermand
new boe ad biologicalexploratio teciques iplasma cell disorders
Chair:P. Greipp & R. Hjek
Myeloma cast epropaty &
amyloidosis
Chair:G. Merlini & R. Comenzo
prIM cologySymposium supported by
novartis cology
Strategies in Evolution:Bone Targeted Therapy for Myeloma
Debate II:Sould we treat some patiets
wit stage I MM?
Chair:M. Gertz ;
V. Mateos & S. Lonial
Pleary abstract sessio I
Chair:M. Cavo & G. Gahrton
Invited speakers:H. Lokhorst &D. Joshua
Moocloal immuoglobuli
ad te erve, Waldes-troms macroglobuliemia
Chair:S. Treon & M. Delforge
Closig ceremoy
Introducing IMW 2013:K. ShimizuPlasma cell Biology
Chair:B. Klein & N. Munshi
hig-risk etities of MM:
from biology to treatmet
Chair:K. Stewart & M. Kuehl
new drugs ad terapeutic
approaces
Chair:J. San Miguel &M. Boccadoro
newly diagosed MM > 65 yrs:facts & questios
Chair:R. Alexanian & A. Palumbo
How I treat?B. Barlogie
What are the current asked questions?Cooperative groups
Milleium akeda& Jasse-Cilag
Symposium
Proteasome inhibition in multiplemyeloma and its clinical implications
Cosesus report
Chair:N. Munshi
Diagnosis criteria & criteria for
treatment and retreatment
Supportive care
Pleary abstractsessio II
Chair:P. Richardson & M. Attal
ucVisit of exhibition & posters area
ucVisit of exhibition & posters area
-
8/8/2019 Preliminary Programme 13th IMW 2011
4/12
USDY MY 3, 2011
I 10:00 - 10:30 OPENING TALK
I 10:30 - 12:30 MOLECLAR PATHWAYS / GENETICSChair:H. Avet-Loiseau- FRA & M. Chesi- USA
Mai lecture: Germinal center and post germinal center differentiation:the cradle of MM ..................................................................................................................................................................... R. Dalla-Favera- USA
The different subtypes of MM ..................................................................................................................................................... R. Fonseca- USAThe genetic progression of MM....................................................................................................................................... H. Avet-Loiseau- FRAMai lecture: MicroRNAs in MM .................................................................................................................................................... C. Croce- USAPanel discussion
I 12:30 - 14:00 LuNch
Visit of exhibition & posters area
I 14:00 - 16:00 PLASMA CELL BIOLOGYChair:B. Klein- FRA & N. Munshi- USA
Introduction lecture: The PR system.............................................................................................................................. A.-H. Lee- USA
Cytokine patways: which one to target? ...................................................................................................................................... B. Klein- FRA
mTOR complex pathway in MM........................................................................................................................................
A. Lichtenstein- USARole of syndecan-1 ............................................................................................................................................................... R.-D. Sanderson- USA
Panel discussion
I 16:00 - 16:30 cOffEE BrEAK
Visit of exhibition & posters area
I 16:30 - 18:30 BONE DISEASE: FROM PHYSIOPATHOLOGY TO TREATMENTChair:R. Bataille- FRA& B. Durie- USA
Introduction lecture: .......................................................................................................................................................... G.-D. Roodman- USA............................................................................................................................................................................................................................ S. Yaccoby- USA............................................................................................................................................................................................................................... N. Giuliani- ITA
............................................................................................................................................................................................................................. B.-P. Ayati- USA
............................................................................................................................................................................................................................ P. Tassone- GBR
............................................................................................................................................................................................................... K. Vanderkerken- BEL
Panel discussion
I 18:30 - 19:15 WALDENSTROMS AWARDIntroduced byR. Kyle- USA
I 20:30 - 23:00 WELCOME RECEPTION AT THE MSE D LORE
PIMInY PGMM
-
8/8/2019 Preliminary Programme 13th IMW 2011
5/12
WDnSDY MY 4, 2011
I8:00 - 10:00NEWLY DIAGNOSED MM < 65 YRS: FACTS & ESTIONSChair:D. Reece- CAN& V. Hungria- BRA
how I treat? ......................................................................................................................................................................................... V. Rajkumar- USA
Wat are te curret asked questios?................................................................................................................... Cooperative groups
EMN ........................................................................................................................................................................................ P. Sonneveld- NED
CTN-BMT........................................................................................................................................................................................ S. Giralt- USA
Pethema...................................................................................................................................................................................... L. Rosiol- ESP
MRC ............................................................................................................................................................................................ G. Morgan- GBR
IFM-DFCI ................................................................................................................................................................................... P. Moreau- FRA
Arkansas ................................................................................................................................................................................. B. Barlogie- USA
I 10:00 - 10:30 cOffEE BrEAK
Visit of exhibition & posters area
I10:30 - 12:30 CELGENE SYMPOSIMe Cotiuum of Care for te Multiple Myeloma PatietChair:K. Anderson- USA & J.-L. Harousseau- FRA
Welcome ad itroductio:The changing dynamic of multiple myeloma treatment .............................................................................. J.-L. Harousseau- FRA
Mechanisms of action and disease: intercellular eventsand immunomodulation ................................................................................................................................................................ S. Lentzsch- USA
Mechanisms of action and disease: immune synapse ............................................................................................. M.-D. Davis- GBR
Optimizing current therapeutic options for relapsed/refractorymultiple myeloma ............................................................................................................................................................... M.-A. Dimopoulos- GRE
The evidence supporting continuous therapy in multiple myeloma ......................................................................... S. Giralt- USA
From bench to bedside: combination regimens in the present and futuremanagement of multiple myeloma ................................................................................................................................ K.-C. Anderson- USA
Close .................................................................................................................................................................................................. K.-C. Anderson- USA
I 12:30 - 14:00 LuNch
Visit of exhibition & posters area
-
8/8/2019 Preliminary Programme 13th IMW 2011
6/12
I 14:00 - 16:00 HIGH-RIS ENTITIES OF MM: FROM BIOLOGY TO TREATMENTChair:K. Stewart- USA& M. Kuehl- USA
t(4& 14) and genomic instability in high-risk MM ...................................................................................................... L. Bergsagel- USA
The biochemical role of the histone methyltransferase MMSET in MM .................................................................... A. Licht- SUI
Whole Genome Sequencing in high-risk MM ..................................................................................................................... K. Stewart- USAWhat is GEP-defined high-risk MM? ........................................................................................................................... J. Shaughnessy- USAThe implications of high-risk MM to therapy ........................................................................ G. Morgan- GBR& H. Einsele- GERPanel discussion
I 16:00 - 16:30 cOffEE BrEAKVisit of exhibition & posters area
I16:30 - 17:30 DEBATE I:POST HIGH DOSE THERAPY, NOTHING, CONSOLIDATION OR MAINTENANCEChair:J. Blad- ESP; M. Attal- FRA & J.-P. Fermand- FRA
I 17:30 - 19:00 NEW BONE AND BIOLOGICAL EXPLORATION TECHNIESIN PLASMA CELL DISORDERSChair:P. Greipp- USA& R. Hjek- CZE
Introduction lecture:Bone imaging in MM: old scaffolds and new avenues ............................................................................. M.-A. Dimopoulos- GRE
Whole-body MRI in MM ........................................................................................................................................................ H. Goldschmidt- GER
Pamidronate: Can the Dose be Lowered? ............................................................................................................................ P. Gimsing- DNE
Zoledronic Acid in the Management of MM ........................................................................................................................ J.-A. Child- GBR
Osteonecrosis of the Jaw ........................................................................................................................................................................ N. Raje- USA
Should we use bone markers? ....................................................................................................................................................... E. Terpos- GREPanel discussion
I 19:00 - 20:30 MYELOMA CAST NEPHROPATHY & AL AMYLOIDOSISChair:G. Merlini- ITA& R. Comenzo- USA
Introduction lecture: New therapeutic approaches in AL ............................................................................. M.-B. Pepys- GBR
Management of AL amyloidosis in 2011 ................................................................................................................................... G. Merlini- ITA
Myeloma cast nephropathy ...................................................... N. Leung- USA& F. Bridoux- FRA &C.-A. Hutchinson- GBR
I20:30 - 21:30 PRIME ONCOLOGY SYMPOSIM SPPORTED BY NOARTIS ONCOLOGYStrategies in Evolution: Bone Targeted therapy for Myeloma
-
8/8/2019 Preliminary Programme 13th IMW 2011
7/12
hUSDY MY 5, 2011
I8:00 - 10:00 NEWLY DIAGNOSED MM > 65 YRS: FACTS & ESTIONSChair:R. Alexanian- USA& A. Palumbo- ITA
how I treat? ........................................................................................................................................................................................... B. Barlogie- USA
Wat are te curret asked questios? .................................................................................................................. Cooperative groups
GIMEMA ................................................................................................................................................................................... A. Palumbo- ITA
Pethema .................................................................................................................................................................................. M. Mateos- ESP
GMMSG ....................................................................................................................................................................................... C. Straka- GER
Hovon/Nordic .......................................................................................................................................................................... A. Waage- NOR
IFM ................................................................................................................................................................................................... T. Facon- FRA
MRC ............................................................................................................................................................................................... F. Davies- GBR
I 10:00 - 10:30 cOffEE BrEAK
Visit of exhibition & posters area
I10:30 - 12:30 MILLENNIM TAEDA & JANSSEN-CILAG SYMPOSIMBiological rationale for proteasome inhibition in multiple myelomaand its clinical implicationsChair & speakers to be announced
Biological basis of proteasome inhibition in MMImpact of proteasome inhibition in the treatment of MM
pdate on clinical studies on proteasome inhibition in MM
Clinical management of peripheral neuropathy in MM
I 12:30 - 14:00 LuNch
Visit of exhibition & posters area
-
8/8/2019 Preliminary Programme 13th IMW 2011
8/12
I 14:00 - 16:00 NEW DRGS AND THERAPETIC APPROACHESChair:M. Boccadoro- ITA & J. San Miguel- ESP
Introduction lecture................................................................................................................................................................... K. Anderson- USA
Preclinical basis for 2nd generation proteasome inhibitors ..................................................................................... D. Chauhan- USA
Carfilzomib and other proteasome inhibitors: Clinical data ..................................................................... A.-J. Jakubowiak- USA
New Imids ........................................................................................................................................................................................................ M. Lacy- USA
Hypomethylating agents in MM ...................................................................................................... J. San Miguel- ESP& E. Ocio- ESP
Monoclonal antibodies in the treatment of MM ......................................................................................................... S. Jagannath- USA
Panel discussion
I 16:00 - 16:30 cOffEE BrEAK
Visit of exhibition & posters area
I16:30 - 17:30 DEBATE II:SHOLD WE TREAT SOME PATIENTS WITH STAGE I MM?Chair:M. Gertz- USA;V. Mateos- ESP&S. Lonial- USA
I17:30 - 19:00 PLENARY ABSTRACT SESSION IChair:M. Cavo- ITA & G. Gahrton- SWE
Invited speakers: H. Lokhorst- NDE& D. Joshua- AUS
I 19:00 - 20:30 MONOCLONAL IMMNOGLOBLIN AND THE NERE, WALDENSTROMSMACROGLOBLINEMIAChair:S. Treon- USA& M. Delforge- BEL
Neuropathy in monoclonal gammopathy ................................................................................................................... E. Nobile-Orazio- ITA
Poems syndrome .......................................................................................................................................................................... A. Dispenzieri- USA
pdate in the treatment of WM ............................................................................................................. S.Treon- USA& V. Leblond- FRA
-
8/8/2019 Preliminary Programme 13th IMW 2011
9/12
FIDY MY 6, 2011
I8:00 - 10:00 CONSENSS REPORTChair:N. Munshi- USA
Diagnosis criteria & criteria for treatment and retreatmentSupportive care including vaccination and infection prophylaxis (E. Anaissie- USA), management of anemia(H. Ludwig- AUT), vein thrombosis (A. Palumbo- ITA,), and bone disease (G.-D. Roodman- USA)
I 10:00 - 10:30 cOffEE BrEAK
Visit of exhibition & posters area
I10:30 - 12:30 PLENARY ABSTRACT SESSION IIChair:P. Richardson- USA& M. Attal- FRA
Invited speaker:A. Spencer- AUS
I 12:30 - 15:00 CLOSING CEREMONYIntroducing IMW 2013 ...................................................................................................................................................................... K. Shimizu- JPN
-
8/8/2019 Preliminary Programme 13th IMW 2011
10/12
CUS DU UV F Pn
CCSS
Carrousel
du Louvre
layoRsialaPervuoLudesuM
1 7
seireliuT
1
iloviR-ervuoL
1
esuMyasrOd
Carrousel
du Louvre
A6
A1
A3
A4
GARE
DAUSTERLITZ
GARE
DE LYON
GARE
DU NORD
GARE
DE LEST
GARE
MONTPARNASSE
GARE
SAINT LAZARE
PORTE DORLANS PORTE DITALIE
PORTE DELA CHAPELLE
A14
LA DFENSE
PORTEMAILLOT
PORTEDAUTEUIL
PORTE
DE BAGNOLET
PORTEDE BERCY
A13
ROISSY CHARLES DE GAULLE
INTERNATIONAL AIRPORT
ORLY INTERNATIONAL
AIRPORT
secalp08
secalp006
RUETIART
RUETIART
ECNARTNEERVUOL
VselrahCllaHecnartne
iloviRedeur99
ellaSertNeL
sqm0091
ellaStolffuoS
sqm529
emroleDsqm0532
ellaS leirbaG
reyoFsqm0021
nedraGlesuorraC
edacragnippohS
edacragnippohS
e*ninazzeM
sqm006
Conference Room
Exhibition / Hospitality suits/ Catering
*Mezzanine: meeting rooms and posters
-
8/8/2019 Preliminary Programme 13th IMW 2011
11/12
Venue: Carrousel du Louvre99 rue de Rivoli
75001 Paris - FRANCE
Dates: May 3-6, 2011
Ofcial Web site: www.myeloma-paris2011.com
Registration: Before March 31, 2011:Reduced fees for early registration: 700 eurosReduced fees for early registration for IMS Member: 550 euros
From April 1st, 2011:Regular fees: 800 euros
Reduced fees for IMS Member: 650 euros
Ofcial language: English
Social event - Welcome Reception: Muse du LouvreMay 3, 2011
Professional Congress Organizer - Europa Organisation
Project Manager: Michal Sertain [email protected]
Partnership Sales Representative: Afaf [email protected]
Registration [email protected]
Hotel reservation Carlson Wagonlit [email protected]
INFORMATION
-
8/8/2019 Preliminary Programme 13th IMW 2011
12/12
INFORMATION
Committees - rgaizig CommitteeJean-Paul FERMAND - Thierry FACON - Philippe MOREA
Under the auspices of the International Myeloma Society and its Board of Directors
Robert A. YLE (President) ania HNGRIA
enneth C. ANDERSON (ice-President) Nikhil MNSHIDouglas E. JOSHA (Secretary) Antonio PALMBOMorie Abraham GERTZ (Treasurer) Jess F. SAN MIGEL
Brian G.M. DRIE azuyuki SHIMIZJean-Luc HAROSSEA Pieter SONNEELD
French Scientic Advisory Committee
Martine AMIOT Jean-Luc HAROSSEABertrand ARNLF Cyrille HLIN
Michel ATTAL Bernard LEIN
Herv AET LOISEA Catherine PELLAT-DECENYNCRgis BATAILLE Claire MATHIOT
International Scientic Advisory Committee
Raymond ALEXANIANBart BARLOGIE
Peter Leif BERGSAGELJoan BLAD
Mario BOCCADOROMichele CAOFaith DAIES
Meletios A. DIMOPOLOSHermann EINSELE
Rafael FONSECAGsta GAHRTON
Sergio GIRALTNicola GILIANI
Sundar JAGANNATH
Henk M. LOHORSTHeinz LDWIGMaria-ictoria MATEOSGiampaolo MERLINIGareth J. MORGANS. incent RAJMARDonna E. REECEPaul G. RICHARDSONJohn D. SHAGHNESSYAndrew SPENCEReith STEWARTSteven TREONarin ANDERERENAnders WAAGE
Platinium sponsors
Bronze sponsors
Others sponsors